
Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)

217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2008; month=10; day=10; hr=9; min=32; sec=25; ms=908;]

Validated By CRFValidator v 1.0.3

Application No: 10658834 Version No: 5.0

Input Set:

Output Set:

Started: 2008-08-27 18:29:50.675 **Finished:** 2008-08-27 18:30:41.822

Elapsed: 0 hr(s) 0 min(s) 51 sec(s) 147 ms

Total Warnings: 198
Total Errors: 88

No. of SeqIDs Defined: 1306
Actual SeqID Count: 1306

Error code		Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (2)
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4)
W	213	Artificial or Unknown found in <213> in SEQ ID (5)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (5)
W	213	Artificial or Unknown found in <213> in SEQ ID (6)
W	213	Artificial or Unknown found in <213> in SEQ ID (7)
W	213	Artificial or Unknown found in <213> in SEQ ID (8)
W	213	Artificial or Unknown found in <213> in SEQ ID (9)
W	213	Artificial or Unknown found in <213> in SEQ ID (10)
W	213	Artificial or Unknown found in <213> in SEQ ID (11)
W	213	Artificial or Unknown found in <213> in SEQ ID (12)
W	213	Artificial or Unknown found in <213> in SEQ ID (13)
W	213	Artificial or Unknown found in <213> in SEQ ID (14)
W	213	Artificial or Unknown found in <213> in SEQ ID (15)
W	213	Artificial or Unknown found in <213> in SEQ ID (16)
W	213	Artificial or Unknown found in <213> in SEQ ID (17)
W	213	Artificial or Unknown found in <213> in SEQ ID (18)
E	355	Empty lines found between the amino acid numbering and the

Input Set:

Output Set:

Started: 2008-08-27 18:29:50.675

Finished: 2008-08-27 18:30:41.822

Elapsed: 0 hr(s) 0 min(s) 51 sec(s) 147 ms

Total Warnings: 198

Total Errors: 88

No. of SeqIDs Defined: 1306

Actual SeqID Count: 1306

Error code		Error Description
E	321	No. of Bases conflict, this line has no nucleotides SEQID (18)
W	213	Artificial or Unknown found in <213> in SEQ ID (19)
W	213	Artificial or Unknown found in <213> in SEQ ID (20)
W	213	Artificial or Unknown found in <213> in SEQ ID (21) This error has occured more than 20 times, will not be displayed
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (44)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (63)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (84)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (97)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (105)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (149)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (188)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (237)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (238)

Input Set:

Output Set:

Started: 2008-08-27 18:29:50.675

Finished: 2008-08-27 18:30:41.822

Elapsed: 0 hr(s) 0 min(s) 51 sec(s) 147 ms

Total Warnings: 198
Total Errors: 88

No. of SeqIDs Defined: 1306

Actual SeqID Count: 1306

Error code		Error Description
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (274)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (332)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (377)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (386)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (441)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (478)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (522)
E	355	Empty lines found between the amino acid numbering and the
E	321	No. of Bases conflict, this line has no nucleotides SEQID (533)
E	355	Empty lines found between the amino acid numbering and the proteins
E	321	No. of Bases conflict, this line has no nucleotides SEQID (564) POS (112)

```
SEQUENCE LISTING
```

165

<210> 2 <211> 165

<110> Gantier, Rene Guyon, Thierry Drittanti, Lila Vega, Manuel <120> RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES <130> 119365-00005/922 <140> 10658834 <141> 2003-09-08 <150> 60/457,135 <151> 2003-03-21 <150> 60/409,898 <151> 2002-09-09 <160> 1306 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 165 <212> PRT <213> Homo sapiens <400> 1 Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met 5 10 Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp 25 Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln 40 Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu 70 75 Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu 85 90 Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys 105 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu 120 125 Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg 135 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser 155 Leu Arg Ser Lys Glu

```
<212> PRT
<213> Artificial Sequence
<223> D2A Mutant IFN-alpha 2b
<400> 2
Cys Ala Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
                                  10
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
           20
                               25
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
                       55
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
                   7.0
                                       75
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
                                  90
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
                              105
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
                                    125
       115
                           120
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
                      135
                                          140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145
                   150
                                      155
Leu Arg Ser Lys Glu
              165
<210> 3
<211> 165
<212> PRT
<213> Artificial Sequence
<220>
<223> P4A Mutant IFN-alpha 2b
<400> 3
Cys Asp Leu Ala Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
                5
                                  10
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
                          40
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
                       55
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
                   70
                                       75
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
               8.5
                                   90
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
                               105
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
                          120
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
                      135
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
```

```
145
                   150
                                       155
                                                           160
Leu Arg Ser Lys Glu
              165
<210> 4
<211> 165
<212> PRT
<213> Artificial Sequence
<223> Q5A Mutant IFN-alpha 2b
<400> 4
Cys Asp Leu Pro Ala Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
                                   10
Leu Leu Ala Gln Met Arq Arq Ile Ser Leu Phe Ser Cys Leu Lys Asp
           20
                               25
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
                           40
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
                       55
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
                   70
                                       75
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
              85
                                  90
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
           100
                              105
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
                                     125
       115
                           120
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
                       135
                                           140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145
                   150
                                      155
                                                           160
Leu Arg Ser Lys Glu
              165
<210> 5
<211> 165
<212> PRT
<213> Artificial Sequence
<220>
<223> T6A Mutant IFN-alpha 2b
<400> 5
Cys Asp Leu Pro Gln Ala His Ser Leu Gly Ser Arg Arg Thr Leu Met
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
                               25
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
                           40
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
                  70
                                       75
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
                                   90
```

Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys

```
100 105 110
```

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu

115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg 130 135 140

Leu Arg Ser Lys Glu

16

<210> 6

<211> 165

<212> PRT

<213> Artificial Sequence

<220>

<223> H7A Mutant IFN-alpha 2b

<400> 6

Cys Asp Leu Pro Gln Thr Ala Ser Leu Gly Ser Arg Arg Thr Leu Met

1 5 10 15

Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe 50 55 60

Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu 65 70 75 80

Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu 85 90 95

Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys 100 105 110

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu 115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg 130 135 140

Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser 145 150 155 160

Leu Arg Ser Lys Glu

165

<210> 7

<211> 165

<212> PRT

<213> Artificial Sequence

<220×

<223> S8A Mutant IFN-alpha 2b

<400> 7

Cys Asp Leu Pro Gln Thr His Ala Leu Gly Ser Arg Arg Thr Leu Met

1 5 10 15

Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln 35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe

```
55
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
                  70
                                    75
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
                                90
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
                            105
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
               120
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
           135
                                       140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145
              150
                                   155
Leu Arg Ser Lys Glu
<210> 8
<211> 165
<212> PRT
<213> Artificial Sequence
<220>
<223> L9A Mutant IFN-alpha 2b
<400> 8
Cys Asp Leu Pro Gln Thr His Ser Ala Gly Ser Arg Arg Thr Leu Met
1
                                10
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
                            25
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
                        40
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
                     55
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
    70
                                    75
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
              85
                                 90
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
       100 105
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
           135
                                       140
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145 150
                                    155
Leu Arg Ser Lys Glu
              165
<210> 9
<211> 165
<212> PRT
<213> Artificial Sequence
<220>
```

<223> G10A Mutant IFN-alpha 2b

<400> 9

Cys Asp Leu Pro Gln Thr His Ser Leu Ala Ser Arg Arg Thr Leu Met

1 5 10 15

Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln 35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe 50 55 60

Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu 65 70 75 80

Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu

85

90

95

Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys 100 105 110

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu 115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg 130 135 140

Leu Arg Ser Lys Glu

165

<210> 10

<211> 165

<212> PRT

<213> Artificial Sequence

<220>

<223> S11A Mutant IFN-alpha 2b

<400> 10

Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ala Arg Arg Thr Leu Met

1 5 10 15

Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp 20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln 35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe 50 55 60

Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu 65 70 75 80

Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu 85 90 95

Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys 100 105 110

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu 115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg 130 135 140

Leu Arg Ser Lys Glu

165

```
<211> 165
<212> PRT
<213> Artificial Sequence
<220>
<223> R12A Mutant IFN-alpha 2b
<400> 11
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Ala Arg Thr Leu Met
                                   10
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
                               25
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
                          40
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
                       55
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
65
                   70
                                       7.5
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
                                   90
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
                               105
           100
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
                          120
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
                      135
Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
145
                   150
                                       155
Leu Arg Ser Lys Glu
               165
<210> 12
<211> 165
<212> PRT
<213> Artificial Sequence
<220>
<223> R13A Mutant IFN-alpha 2b
<400> 12
Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Ala Thr Leu Met
1
Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
                               25
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
                       55
Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
                                       75
                   70
Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
                             105
          100
Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
                           120
Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
```

130 135 140

Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn